People: Pluristem Therapeutics Inc (PSTI.PH)

PSTI.PH on Philadelphia Stock Exchange

2.67USD
7 Aug 2014
Price Change (% chg)

$-0.28 (-9.49%)
Prev Close
$2.95
Open
$2.67
Day's High
$2.67
Day's Low
$2.67
Volume
100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Zami Aberman

59 2014 Chairman of the Board, Chief Executive Officer

Yaky Yanay

42 2014 President, Chief Operating Officer

Boaz Gur-Lavie

40 2014 Chief Financial Officer, Secretary

Doron Shorrer

60 2006 Lead Independent Director

Issac Braun

60 2005 Director

Mark Germain

63 2009 Director

Moria Kwiat

34 2012 Director

Hava Meretzki

44 2005 Director

Israel Ben-Yoram

52 2005 Independent Director

Nachum Rosman

67 2007 Independent Director

Karine Kleinhaus

2013 Divisional Vice President, North-America

Biographies

Name Description

Zami Aberman

Mr. Zami Aberman is Chairman of the Board, Chief Executive Officer of Pluristem Therapeutics, Inc. Mr. Aberman became Chief Executive Officer and President in September 2005 and a director of the Company in November 2005. Mr. Aberman has served as Chairman of the Board since April 2006, and between May 2007 and February 2009 he was Co-Chairman with Mr. Mark Germain. He has 25 years of experience in marketing and management in the high technology industry. Mr. Aberman has held positions of Chief Executive Officer and Chairman positions in companies in Israel, the United States, Europe, Japan and Korea. Mr. Aberman operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. He has serves as the chairman of Rose Hitech Ltd., a private investment company. He has served in the past as the chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., a company involved in data management. Prior to that, Mr. Aberman served as the President and CEO of Elbit Vision System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. Prior to his service with the Company, Mr. Aberman has served as President and CEO of Netect Ltd., specializing in the field of internet security software and was the Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He has also served as Chairman of Display Inspection Systems Inc., specializing in laser based inspection machines and as President and CEO of Robomatix Technologies Ltd. In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.

Yaky Yanay

Mr. Yaky Yanay, CPA, is President, Chief Operating Officer of Pluristem Therapeutics, Inc. Mr. Yanay was appointed as the registrant’s Chief Financial Officer and Secretary in November 2006, and Executive Vice President in March 2013. Prior to joining the registrant, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company traded over the OTC Bulletin Board. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay serves as a director of Elbit Vision Systems Ltd. He is a member of the board of directors of Israel Advanced Technologies Industries (IATI), the largest umbrella organization in Israel for companies, organizations, and individuals in the high tech and life science sectors. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.

Boaz Gur-Lavie

Mr. Boaz Gur-Lavie is Chief Financial Officer, Secretary of the Company. Mr. Gur-Lavie was appointed as the registrant’s Vice President of Finance on January 1, 2014. Prior to joining the registrant, beginning in 2010 Mr. Gur-Lavie was Chief Financial Officer of Abbott Informatics Solutions Division, an umbrella organization with P&L responsibility for different Abbott informatics brands as well as STARLIMS, which develops software for the laboratory information management systems industry. Prior to the acquisition of STARLIMS by Abbott Informatics Division in 2010, he was STARLIMS’ Vice President of Finance, beginning in 2005. Before joining STARLIMS, Mr. Gur-Lavie was the assistant controller of ECI since 2004, and was on the ERS team of Deloitte Israel between 2000 and 2003. He has also served as a lecturer at the Ben Gurion University. Mr. Gur-Lavie holds a master’s degree in finance and a bachelor’s degree in economy and accounting from the University of Ben-Gurion. He is also a Certified Public Accountant in Israel.

Doron Shorrer

Mr. Doron Shorrer, CPA, is Lead Independent Director of Pluristem Therapeutics, Inc. Mr. Shorrer was one of the Company’s founders and served as its first Chairman until 2006. Mr. Shorrer also serves as a director of other companies: Omer Insurance Mutual Fund, Provident Fund for employees of the Israel Electric Company Ltd. and for Hebrew University employees, and Massad Bank from the International Bank group. Between 1999 and 2004 he was Chairman of the Boards of Phoenix Insurance Company, one of the largest insurance companies in Israel, and of Mivtachim Pension Funds Group, the largest pension fund in Israel. Prior to serving in these positions, Mr. Shorrer held senior positions that included Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; Member of the board of directors of “Nechasim” of the State of Israel; Member Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Founder and managing partner of an accounting firm with offices in Jerusalem, Tel-Aviv and Haifa; Member of the Lecture Staff of the Hebrew University Business Administration School; Chairman of Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy. Among many areas of expertise, Mr. Shorrer formulates implements and administers business planning in the private and institutional sector in addition to consulting on economic, accounting and taxation issues to a large audience ranging from private concerns to government ministries.Mr. Shorrer holds a B.A. in Economics and Accounting and an M.A. in Business Administration (specialization in finance and banking) from the Hebrew University of Jerusalem and is a Certified Public Accountant (ISR).

Issac Braun

Mr. Issac Braun is Director of Pluristem Therapeutics, Inc. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He is a co-founder and has been a board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun is involved with advising private companies on raising capital and business development.

Mark Germain

Mr. Mark S. Germain is Director of Pluristem Therapeutics, Inc. Between May 2007 and February 2009, Mr. Germain served as Co-Chairman of our Board. For more than five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries. He has been involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company, which was sold in 1991. In addition to being a Director of the Company, Mr. Germain is a director of ChromaDex, Inc. (CDXB.OB), a publicly traded company. Mr. Germain also serves as a director of the following companies that were reporting companies in the past: Stem Cell Innovations, Inc., Omnimmune Corp. and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in and outside the biotechnology field.

Moria Kwiat

Ms. Moria Kwiat serves as Director of Pluristem Therapeutics, Inc. Dr. Kwiat holds a B.Sc and an M.Sc. in Biotechnology from the Department of Molecular Microbiology and Biotechnology at Tel Aviv University, and a Ph.D.in Nano-Biotechnology from the Department of Material and Nanoscience at the Faculty of Chemistry of Tel Aviv University. Dr. Kwiat served as a teaching assistant at Tel Aviv University from 2003 through 2012. Currently, Dr. Kwiat is a postdoc fellow at the Faculty of Chemistry of Tel Aviv University, working with various cell types such as cancer and neuron cells on nano material platforms.

Hava Meretzki

Ms. Hava Meretzki is Director of Pluristem Therapeutics, Inc. Ms. Meretzki is an attorney and is a partner in Meretzki law firm in Haifa, Israel. Ms. Meretzki specializes in civil, trade and labor law, and is presently a member of the Central Committee of the National Council of the Israel Bar Association.Ms. Meretzki received a Bachelors Degree in Law from the Hebrew University in 1991 and was admitted to the Israel Bar Association in 1993.

Israel Ben-Yoram

Mr. Israel Ben-Yoram is Independent Director of Pluristem Therapeutics, Inc. He has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985. In addition, since 1992, Mr. Ben-Yoram has been a shareholder and has served as the head director of Mor, Ben-Yoram Ltd., a private company in Israel in parallel to the operation of Mor, Ben-Yoram and Partners. This company provides management services, economic consulting services and other professional services to businesses. Furthermore, Mr. Ben-Yoram is the CEO of Eshed Dash Ltd. and Zonbit Ltd. During 2003-2004 Mr. Ben-Yoram served as a director of Brainstorm Cell Therapeutics Inc. (BCLI) and Smart Energy solutions, Inc. (SMGY), both of which were traded on the NASDAQ. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in Economics from the Hebrew University of Jerusalem, an LL.B. and an MBA from Tel Aviv University and an LL.M. from Bar Ilan University. In addition, Mr. Ben-Yoram is qualified in arbitration and in mediation.

Nachum Rosman

Mr. Nachum Rosman is Independent Director of Pluristem Therapeutics, Inc. He provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations. Mr. Rosman also serves as a director at several privately held companies. Throughout his career, Mr. Rosman held Chief Executive Officer and Chief Financial Officer positions in Israel, the United States and England. In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales. Mr. Rosman holds a B.Sc. in Management Engineering and an M.Sc. in Operations Research from the Technion, Haifa, Israel. Mr. Rosman also participated in a Ph.D. program in Investments and Financing at the Tel Aviv University, Israel.

Karine Kleinhaus

Basic Compensation

Options Compensation

Name Options Value

Zami Aberman

60,500,000 0

Yaky Yanay

12,500,000 0

Boaz Gur-Lavie

0 0

Doron Shorrer

12,851,170 0

Issac Braun

8,284,594 0

Mark Germain

50,000,001 0

Moria Kwiat

0 0

Hava Meretzki

8,538,377 0

Israel Ben-Yoram

8,355,089 0

Nachum Rosman

0 0

Karine Kleinhaus

0 0
Search Stocks